DACH2

Summary

DACH2 (dachshund family transcription factor 2, HGNC:16814) is a protein-coding gene on chromosome Xq21.2, encoding Dachshund homolog 2 (Q96NX9). Transcription factor that is involved in regulation of organogenesis.

This gene is one of two genes which encode a protein similar to the Drosophila protein dachshund, a transcription factor involved in cell fate determination in the eye, limb and genital disc of the fly. The encoded protein contains two characteristic dachshund domains: an N-terminal domain responsible for DNA binding and a C-terminal domain responsible for protein-protein interactions. This gene is located on the X chromosome and is subject to inactivation by DNA methylation. The encoded protein may be involved in regulation of organogenesis and myogenesis, and may play a role in premature ovarian failure. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 117154 — RefSeq curated summary.

At a glance

• Gene–disease (curated): primary ovarian failure (Limited, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 124 total
• MANE Select transcript: NM_053281

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16814
Approved symbol	DACH2
Name	dachshund family transcription factor 2
Location	Xq21.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000126733
Ensembl biotype	protein_coding
OMIM	300608
Entrez	117154

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 5 protein_coding, 2 nonsense_mediated_decay

ENST00000373125, ENST00000373131, ENST00000461604, ENST00000484479, ENST00000506327, ENST00000508860, ENST00000510272

RefSeq mRNA: 3 — MANE Select: NM_053281 NM_001139514, NM_001139515, NM_053281

CCDS: CCDS14455, CCDS48140, CCDS55457

Canonical transcript exons

ENST00000373125 — 12 exons

Exon	Start	End
ENSE00001634305	86714548	86714720
ENSE00003473900	86832106	86832602
ENSE00003478843	86514279	86514391
ENSE00003540694	86813130	86813277
ENSE00003554728	86376824	86376862
ENSE00003555518	86816034	86816099
ENSE00003562053	86695021	86695179
ENSE00003620452	86739747	86739882
ENSE00003660790	86651036	86651167
ENSE00003663002	86812856	86813004
ENSE00003671089	86814688	86814834
ENSE00003844511	86148451	86149108

Expression profiles

Bgee: expression breadth ubiquitous, 124 present calls, max score 92.49.

FANTOM5 (CAGE): breadth broad, TPM avg 2.0957 / max 301.4259, expressed in 312 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
196849	1.0169	262
196852	0.9759	90
196850	0.0575	20
196851	0.0455	15

Top tissues by expression

225 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	92.49	gold quality
Brodmann (1909) area 23	UBERON:0013554	91.86	gold quality
middle temporal gyrus	UBERON:0002771	87.52	gold quality
entorhinal cortex	UBERON:0002728	85.07	gold quality
oviduct epithelium	UBERON:0004804	84.48	gold quality
superior frontal gyrus	UBERON:0002661	82.47	gold quality
postcentral gyrus	UBERON:0002581	79.89	silver quality
nucleus accumbens	UBERON:0001882	79.10	gold quality
ventricular zone	UBERON:0003053	78.54	gold quality
Ammon’s horn	UBERON:0001954	78.40	gold quality
prefrontal cortex	UBERON:0000451	77.77	gold quality
parietal lobe	UBERON:0001872	77.71	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	77.52	gold quality
Brodmann (1909) area 9	UBERON:0013540	77.46	gold quality
temporal lobe	UBERON:0001871	77.38	gold quality
cerebral cortex	UBERON:0000956	77.16	gold quality
islet of Langerhans	UBERON:0000006	76.75	gold quality
anterior cingulate cortex	UBERON:0009835	76.54	gold quality
frontal cortex	UBERON:0001870	76.33	gold quality
neocortex	UBERON:0001950	76.09	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	75.93	gold quality
hypothalamus	UBERON:0001898	75.75	gold quality
Brodmann (1909) area 46	UBERON:0006483	74.97	gold quality
caudate nucleus	UBERON:0001873	74.24	gold quality
amygdala	UBERON:0001876	73.80	gold quality
forebrain	UBERON:0001890	73.11	gold quality
putamen	UBERON:0001874	72.38	gold quality
primary visual cortex	UBERON:0002436	71.78	gold quality
right uterine tube	UBERON:0001302	71.69	gold quality
right frontal lobe	UBERON:0002810	71.69	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-2	yes	8804.15
E-ANND-3	yes	4.57

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
HELT
MYOG	Repression

Upstream regulators (CollecTRI, top): MYOG

miRNA regulators (miRDB)

49 targeting DACH2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-379-3P	99.69	69.60	1524
HSA-MIR-411-3P	99.69	69.63	1524
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-1251-3P	99.64	67.21	1408
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-4756-3P	99.62	66.30	1319

Literature-anchored findings (GeneRIF, showing 3)

• Most X;autosome translocations associated with premature ovarian failure do not interrupt X-linked genes. Only one of the six breakpoints disrupts a gene, DACH2. (PMID:12438735)
• Exome sequencing in two brothers with distinct phenotype including congenital language disorder, growth retardation, intellectual disability and urinary and fecal incontinence, identifies missense mutations in ABCD1 and DACH2. (PMID:25234129)
• DACH2 is an independent prognostic marker that can be used at initial diagnosis of urothelial carcinoma of the bladder to identify patients who have a high potential to develop metastasis. (PMID:25744029)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	dacha	ENSDARG00000010132
danio_rerio	dachb	ENSDARG00000034785
mus_musculus	Dach2	ENSMUSG00000025592
rattus_norvegicus	Dach2	ENSRNOG00000004869
drosophila_melanogaster	dac	FBGN0005677
caenorhabditis_elegans		WBGENE00000895

Paralogs (1): DACH1 (ENSG00000276644)

Protein

Protein identifiers

Dachshund homolog 2 — Q96NX9 (reviewed: Q96NX9)

All UniProt accessions (4): Q96NX9, D6REJ4, D6RFG7, H0Y912

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor that is involved in regulation of organogenesis. Seems to be a regulator for SIX1 and SIX6. Seems to act as a corepressor of SIX6 in regulating proliferation by directly repressing cyclin-dependent kinase inhibitors, including the p27Kip1 promoter. Is recruited with SIX6 to the p27Kip1 promoter in embryonal retina. SIX6 corepression also seems to involve NCOR1, TBL1, HDAC1 and HDAC3. May be involved together with PAX3, SIX1, and EYA2 in regulation of myogenesis. In the developing somite, expression of DACH2 and PAX3 is regulated by the overlying ectoderm, and DACH2 and PAX3 positively regulate each other’s expression. Probably binds to DNA via its DACHbox-N domain.

Subunit / interactions. Interacts with SIX6 and EYA2.

Subcellular location. Nucleus.

Domain organisation. The DACHbox-N/DD1 domain forms a structure containing a DNA binding motif similar to that of the forkhead/winged helix domain.

Similarity. Belongs to the DACH/dachshund family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q96NX9-1	1	yes
Q96NX9-2	2
Q96NX9-3	3
Q96NX9-4	4

RefSeq proteins (3): NP_001132986, NP_001132987, NP_444511* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003380	SKI/SNO/DAC	Domain
IPR009061	DNA-bd_dom_put_sf	Homologous_superfamily
IPR037000	Ski_DNA-bd_sf	Homologous_superfamily
IPR052417	Dachshund_domain	Family

Pfam: PF02437

UniProt features (13 total): region of interest 5, splice variant 4, compositionally biased region 2, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96NX9-F1	62.69	0.32

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 84 (showing top): BENPORATH_ES_WITH_H3K27ME3, NFKB_C, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, GOBP_FEMALE_SEX_DIFFERENTIATION, GOBP_SEX_DIFFERENTIATION, AACTTT_UNKNOWN, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, CDPCR3HD_01, GOBP_DEVELOPMENT_OF_PRIMARY_SEXUAL_CHARACTERISTICS, GOCC_TRANSCRIPTION_REGULATOR_COMPLEX, OSF2_Q6, SMAD4_Q6, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, SMAD_Q6, GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_DN

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), development of primary female sexual characteristics (GO:0046545)

GO Molecular Function (3): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA binding (GO:0003677)

GO Cellular Component (2): nucleus (GO:0005634), transcription regulator complex (GO:0005667)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
development of primary sexual characteristics	1
female sex differentiation	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
nucleic acid binding	1
intracellular membrane-bounded organelle	1
protein-containing complex	1

Protein interactions and networks

STRING

808 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DACH2	EYA2	O00167	727
DACH2	POF1B	Q8WVV4	669
DACH2	SATL1	Q86VE3	590
DACH2	HDAC9	Q9UKV0	583
DACH2	IL1RAPL2	Q9NP60	542
DACH2	MYOG	P15173	533
DACH2	DIAPH2	O60879	506
DACH2	HDAC4	P56524	493
DACH2	KLHL4	Q9C0H6	489
DACH2	SIX1	Q15475	478
DACH2	XPNPEP2	O43895	456
DACH2	APOOL	Q6UXV4	456
DACH2	NCOR1	O75376	436
DACH2	FARSB	Q9NSD9	436
DACH2	CPXCR1	Q8N123	434

IntAct

8 interactions, top by confidence:

A	B	Type	Score
TRIM44	ODAD3	psi-mi:“MI:0914”(association)	0.530
DACH2	ATP6V1G1	psi-mi:“MI:0915”(physical association)	0.400
DACH2	TSC1	psi-mi:“MI:0915”(physical association)	0.370
IRF9	DACH2	psi-mi:“MI:0915”(physical association)	0.370
DACH2	CFTR	psi-mi:“MI:0915”(physical association)	0.370
DACH2	GYG2	psi-mi:“MI:0914”(association)	0.350
DACH2	TRIM26	psi-mi:“MI:0914”(association)	0.350

BioGRID (24): GYG2 (Affinity Capture-MS), DACH1 (Affinity Capture-MS), DACH2 (Affinity Capture-MS), TRIM26 (Affinity Capture-MS), CD2AP (Affinity Capture-MS), DACH2 (Proximity Label-MS), DACH2 (Positive Genetic), DACH2 (Two-hybrid), DACH2 (Affinity Capture-RNA), DACH1 (Affinity Capture-MS), TRIM26 (Affinity Capture-MS), CD2AP (Affinity Capture-MS), GYG2 (Affinity Capture-MS), DACH2 (Affinity Capture-MS), DACH2 (Proximity Label-MS)

ESM2 similar proteins: A0A0G2JTZ2, A2BEA6, A4IFD2, B1H349, B3DM43, B3DM47, F1M8W4, O15409, O75030, P0CF24, P23899, P27889, P35680, P35710, P35711, P35712, P40645, P40647, P58463, P70062, P70063, P70064, Q23045, Q2LE08, Q4VYR7, Q4VYS1, Q58NQ4, Q5QL03, Q5RCU4, Q5RER5, Q5W1J5, Q6GL68, Q800Q5, Q86MD3, Q8HZ00, Q8MJ97, Q8MJ98, Q8MJ99, Q8MJA0, Q8STF6

Diamond homologs: H2KY91, Q1XH10, Q80YR3, Q925Q8, Q96NX9, Q9QYB2, Q9UI36, A7M7C7, P12755, P12757, P17863, P49140, P84550, P84551, Q02225, Q1LXZ9, Q2VWA4, Q5R431, Q60665, Q60698, Q8BX46, Q9TUG2

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
DACH2	“down-regulates quantity by repression”	MYOG	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

124 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	71
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

3329 predictions. Top by Δscore:

Variant	Effect	Δscore
X:86149104:GCCAG:G	donor_gain	1.0000
X:86149107:AGG:A	donor_loss	1.0000
X:86149110:T:G	donor_loss	1.0000
X:86514274:A:AG	acceptor_gain	1.0000
X:86514276:CA:C	acceptor_loss	1.0000
X:86514277:A:AG	acceptor_gain	1.0000
X:86514278:G:GT	acceptor_gain	1.0000
X:86594508:A:G	donor_gain	1.0000
X:86651033:TAGGT:T	acceptor_loss	1.0000
X:86651034:A:C	acceptor_loss	1.0000
X:86651035:GGT:G	acceptor_gain	1.0000
X:86651163:CACAG:C	donor_gain	1.0000
X:86651164:ACAG:A	donor_gain	1.0000
X:86651165:CAGG:C	donor_loss	1.0000
X:86651166:AG:A	donor_gain	1.0000
X:86651166:AGGTG:A	donor_loss	1.0000
X:86651167:GG:G	donor_gain	1.0000
X:86651168:G:C	donor_loss	1.0000
X:86651168:G:GG	donor_gain	1.0000
X:86149068:A:T	donor_gain	0.9900
X:86149109:G:GG	donor_gain	0.9900
X:86206751:A:AG	acceptor_gain	0.9900
X:86206752:G:GG	acceptor_gain	0.9900
X:86256740:A:AG	acceptor_gain	0.9900
X:86376040:A:T	donor_gain	0.9900
X:86514275:A:G	acceptor_gain	0.9900
X:86514278:GT:G	acceptor_gain	0.9900
X:86514278:GTT:G	acceptor_gain	0.9900
X:86514278:GTTC:G	acceptor_gain	0.9900
X:86514278:GTTCA:G	acceptor_gain	0.9900

AlphaMissense

3943 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:86148862:T:C	F81S	1.000
X:86148888:T:C	C90R	1.000
X:86148889:G:A	C90Y	1.000
X:86148890:C:G	C90W	1.000
X:86148903:T:C	F95L	1.000
X:86148905:T:A	F95L	1.000
X:86148905:T:G	F95L	1.000
X:86148912:T:C	F98L	1.000
X:86148913:T:C	F98S	1.000
X:86148914:T:A	F98L	1.000
X:86148914:T:G	F98L	1.000
X:86148916:T:C	L99P	1.000
X:86148933:G:C	G105R	1.000
X:86148939:C:G	H107D	1.000
X:86148956:G:C	K112N	1.000
X:86148956:G:T	K112N	1.000
X:86148958:T:C	L113P	1.000
X:86148987:T:C	C123R	1.000
X:86148988:G:A	C123Y	1.000
X:86148989:T:G	C123W	1.000
X:86149003:T:A	V128D	1.000
X:86149012:T:A	L131H	1.000
X:86149012:T:C	L131P	1.000
X:86149030:T:A	I137N	1.000
X:86149046:C:A	N142K	1.000
X:86149046:C:G	N142K	1.000
X:86149050:T:A	C144S	1.000
X:86149050:T:C	C144R	1.000
X:86149051:G:A	C144Y	1.000
X:86149051:G:C	C144S	1.000

dbSNP variants (sampled 300 via entrez): RS1000001044 (X:86453676 T>G), RS1000001647 (X:86504807 T>A), RS1000001842 (X:86340933 A>G), RS1000008373 (X:86530438 T>C), RS1000013553 (X:86397316 T>A), RS1000019318 (X:86634137 C>A,T), RS1000029302 (X:86802508 G>A,T), RS1000039613 (X:86462374 T>C), RS1000048496 (X:86540012 T>C), RS1000049536 (X:86495133 C>T), RS1000054749 (X:86400685 A>G), RS1000065040 (X:86164819 C>G,T), RS1000065757 (X:86811465 T>C), RS1000065875 (X:86704509 C>A,G), RS1000069576 (X:86755893 G>A)

Disease associations

OMIM: gene MIM:300608 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
primary ovarian failure	Limited	Autosomal dominant

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST003991_20	Childhood ear infection	4.000000e-07
GCST009391_338	Metabolite levels	2.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007904	susceptibility to childhood ear infection measurement
EFO:0010433	triacylglycerol 56:6 measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, increases methylation	8
Aflatoxin B1	decreases methylation, increases methylation, affects expression	3
Panobinostat	affects cotreatment, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
methyleugenol	decreases expression	1
trichostatin A	increases expression	1
arsenite	increases methylation	1
manganese chloride	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Arsenic Trioxide	increases expression	1
Acetaminophen	increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Manganese	increases expression	1
Tretinoin	increases expression	1
8-Bromo Cyclic Adenosine Monophosphate	decreases expression	1

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists